The WVU Cancer Institute welcomes Mike Ridinger, R.N., M.B.A., as assistant director of finance and administration and the administrator of Hematology/Oncology.
Ridinger is a graduate from Seton Hall University with over fifteen years of experience within the health and medical systems. His background includes understanding and utilizing economic, financial, market, and industry segment data to identify key issues and implications for potential strategies and plans.
Ridinger has experience implementing strategic imperatives within academic and private healthcare environments in order to lead and drive change. He has an in-depth knowledge of market forces and the ability to function in highly competitive markets and the ability to build lasting relationships with internal and external strategic partners.
“Mike's extensive experience, overall vision and clinical expertise will help to guide the growth of the section of hematology/oncology,” Richard Funnell, vice president of cancer services, said.
“This experience will be of great service to our physicians and patients as we continue to grow the WVU Cancer Institute,“ Richard Goldberg, M.D., director of the WVU Cancer Institute, said. "He brings with him a wealth of experiences that will help us to develop our programs."
As assistant director of finance and administration and the administrator of Hematology/Oncology, Ridinger’s primary function will be to support Hematology and Oncology faculty, mid-level providers, and oversee WVU Medicine, University Healthcare Associates, Foundation, and WVU Research Corporation budgets for the WVU Cancer Institute and the section of Hematology/Oncology.
The WVU Cancer Institute will begin enrolling its first patients in a National Institute of Health (NIH) Beau Biden Moonshot Initiative trial on Oct. 25 as part of a consortium of six U.S. healthcare systems with the goal of integrating the use of patient-reported outcomes into the routine practice of oncology.